Pre-made Rozanolixizumab benchmark antibody ( Whole mAb, anti-FCGRT therapeutic antibody, Anti-FCRN/FcgammaRn/alpha-chain Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Rozanolixizumab biosimilar, Whole mAb, Anti-FCGRT Antibody: Anti-FCRN/FcgammaRn/alpha-chain therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Rozanolixizumab (UCB7665) is an investigational humanized monoclonal IgG antibody being developed by UCB for the treatment of myasthenia gravis (MG), a neuromuscular condition thought to be triggered by an autoimmune response.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-498-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Rozanolixizumab biosimilar, Whole mAb, Anti-FCGRT Antibody: Anti-FCRN/FcgammaRn/alpha-chain therapeutic antibody
INN Name	Rozanolixizumab
Target	FCGRT
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	6fgb:HL
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2016
Year Recommended	2017
Companies	UCB
Conditions Approved	na
Conditions Active	Chronic inflammatory demyelinating polyradiculoneuropathy;Idiopathic thrombocytopenic purpura;Myasthenia gravis
Conditions Discontinued	Immunological disorders
Development Tech	na